Search

Feel the way you want this 420 with Grön edibles. Grab Pearls and Megas for 30% off at select retailers in New Jersey. The post Make 420 mega with 30% off from Grön appeared first on Leafly. < Back Make 420 mega with 30% off from Grön Mar 25, 2025 Anna Elliott Leafly Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Feel the way you want this 420 with Grön edibles. Grab Pearls and Megas for 30% off at select retailers in New Jersey. The post Make 420 mega with 30% off from Grön appeared first on Leafly. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

This recipe for mac and cheese is infused with cannabis. The crunch comes from a topping mix of tortilla chips, potato chips, and buttery snack crackers. The recipe includes ingredients and directions for making the dish. < Back Edibles Recipe: Mac & Cheese Gets Toasted Jan 8, 2025 Laurie and MaryJane Cannabis Now Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Mac and cheese is truly a treasure, as it is both one of the most popular comfort foods *and* easy to infuse with cannabis. The results are cheesy, creamy and deliciously crunchy. Instead of the standard breadcrumbs, the crunch in this mac and cheese comes from the topping mix of tortilla chips, potato chips and buttery snack crackers — which can also be infused if you’re looking to pack an extra punch. Also, thanks to the food miracles of modern science, you can substitute gluten-free pasta and crackers or dairy-free cheese to modify the recipe to fit your dietary needs. I’ve tried these versions and they’re not bad at all. Not great, but not bad. In this recipe, the canna-butter is infused into the three-cheese sauce, so you can rest assured the servings will all contain a homogenous serving of THC as long as you spread the cheese sauce evenly. You can calculate the potency you desire by purchasing labeled canna-butter or making it yourself. If you choose to DIY, simply multiply the amount of flower you’re using by the percentage (in decimal form) of THC in the flower and that will tell you how strong your canna-butter is, though a small amount may burn off in the cooking process. If you are a heavy hitter, you can also use some canna-butter to sauté the toppings, but one thing I try to stress is not to overdo the amount of cannabis in your food. Take it slow, get to know your dose and be considerate of others. You can always put some of infused toppings in a bowl at your adults-only table, so folks can help themselves to a higher potency if they wish. *INGREDIENTS — Serves 8-10* - 1 lb. pasta shells, or your preferred choice of shape - 7 tablespoons butter - 4 tablespoons cannabis-infused butter - ½ cup all-purpose flour - 1 ½ cups whole milk - 2 ½ cups half-and-half - 4 cups cheddar, shredded - 1 cup Swiss cheese, shredded - 1 cup whole milk mozzarella, shredded - 2 teaspoons salt - 1 teaspoon coarse black pepper - 1 large yellow onion, peeled and thinly sliced - 10 oz. spinach - 1 cup potato chips, crushed - 1 cup buttery snack crackers, crushed - ½ cup tortilla chips, crushed *DIRECTIONS* 1. Heat oven to 340° Fahrenheit with the oven rack in the middle. 2. Use about 1 tablespoon of butter to line the edges of a large casserole dish. I used an 8 ½ by 10-inch dish. 3. In a pot of boiling water, cook the pasta until al dente. Drain and run under cold water to stop the cooking. 4. In a saucepan, melt 4 tablespoons of cannabis-infused butter with 4 tablespoons of regular butter. Whisk in the flour to make a roux and stir for about 3 minutes, whisking constantly. Slowly whisk in the milk and the half-and-half until smooth. Stir in the cheeses over low heat until the cheese is melted and the sauce has thickened, about 8-10 minutes. Remove from heat. 5. In a medium sauté pan, heat 1 tablespoon of non-infused butter and cook the onion until it is caramelized and golden brown, about 8-10 minutes. Add the spinach and stir to combine until the spinach wilts. Set aside. 6. Combine the pasta and the onion/spinach mixture with the cheese sauce, mixing very well to distribute the cheese evenly. Pour into the large buttered casserole dish. 7. In the sauté pan, melt 1 tablespoon of butter. Add the crushed potato chips, crackers and tortilla chips and sauté until coated with the butter. Top the mac and cheese in the casserole dish with the crumb mixture. Bake until top is golden and edges of dish are bubbling, which should take about 25-30 minutes. Enjoy! *TELL US*, what’s your favorite mac & cheese add-on? *Originally published in Issue 35 of Cannabis Now. LEARN MORE* The post Edibles Recipe: Mac & Cheese Gets Toasted appeared first on Cannabis Now. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Oklahoma Gov. Kevin Stitt (R) called intoxicating hemp products a danger and urged state officials to restrict them, as reported by FOX 23. The governor cited psychoactive cannabinoids, including delta-8 THC, and called for action. These statements follow a downturn in the state’s medical cannabis industry. < Back Oklahoma Gov. Targets Intoxicating Hemp Products Apr 30, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Oklahoma Gov. Kevin Stitt (R) in a letter released Monday called intoxicating hemp products a danger to public health and safety, and called on state officials to coordinate and enact restrictions on the products, FOX 23 reports. The letter was addressed to Secretary of Public Safety Tricia Everest, Oklahoma Bureau of Narcotics and Dangerous Drugs Control Director Donnie Anderson, Oklahoma Medical Marijuana Authority (OMMA) Executive Director Adria Berry, Department of Public Safety Commissioner Tim Tipton, and Oklahoma State Bureau of Investigation Director Greg Mashburn, the report said. The governor highlighted several psychoactive cannabinoids that can be derived from industrial hemp in the letter — including delta-8 THC, delta-10 THC, tetrahydrocannabinol-O acetate (THC-O) — and called on the officials and their respective agencies to “work together to identify and investigate the presence of [the compounds] and as appropriate to your agency’s authority, to take action within your jurisdictional lane.” “These compounds, often marketed to young people, have psychoactive properties that threaten the safety and well-being of Oklahomans. We must act quickly and collaboratively to address this emerging threat and ensure that both licensed and illicit markets are held accountable.” — Gov. Stitt, in the letter The governor’s statements follow over two years of downturn for the state’s medical cannabis industry after lawmakers set a moratorium in 2022 on new licenses. A report last December found that the number of Oklahoma cannabis operators dropped by one-third in the previous year. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

California's largest retail cannabis chain, Stiiizy, won an auction to acquire 12 dispensaries from the defunct Gold Flora for $25 million, though the original bid was reduced after the discovery that three licenses could not be transferred. A competitor, Sweet Leaf, unsuccessfully challenged the sale, arguing their higher initial bid should have prevailed after Stiiizy's reduction, but a Los Angeles County judge rejected the attempt. < Back Stiiizy Acquires 12 Gold Flora Dispensaries for $25M at Auction Dec 11, 2025 TG Branfalt Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link California’s largest retail cannabis chain, Stiiizy, on Monday gained control of 12 dispensaries previously owned by the now-defunct Gold Flora, SFGate reports. Stiiizy bought Gold Flora’s leases and licenses with a $25 million auction bid on October 23, according to a court order filed in Los Angeles Superior Court. In a statement to SFGate, Stiiizy President Tak Sato said the company now owns 58 retail shops in California and three in Michigan. The bid was initially for $26.45 million, but was reduced after Stiiizy discovered that three licenses – in San Jose, Costa Mesa, and Santa Barbara – could not be transferred to new ownership, according to the court filing outlined by SFGate. Sweet Leaf, a competitor in the auction, said that its $26.3 million bid should have ultimately won out because their bid was higher than Stiiizy’s after the post-auction reduction. In a petition to make Sweet Leaf the highest bidder, attorney for the firm said Stiiizy “had months to conduct due diligence and knew that the sale was on ‘AS IS’ terms, and so it should have factored such risks into its bid.” A Los Angeles County judge ultimately rejected Sweet Leaf’s attempt to stop the sale. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Federal prosecutors uncovered a multi-year drug trafficking conspiracy spanning the Mid-Atlantic that operated out of a Newport News luxury car dealership. The organization's leader, Cortez Dayshawn Bumphus, was sentenced to 40 years in prison on drug, firearm, and money laundering charges. < Back Luxury car dealership served as hub for Virginia drug trafficking ring, Newport News man sentenced to 40 years Jan 6, 2026 Editorial Staff Outlaw Report Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Federal prosecutors say a Newport News luxury car dealership was used as a base of operations for a multi-year drug trafficking conspiracy spanning the Mid-Atlantic. The organization’s leader, Cortez Dayshawn Bumphus, was sentenced to 40 years in prison following his conviction on drug, firearm, and money laundering charges. Source < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

D.C. is considering extending conditional licenses to four years due to ABCA crackdowns. Maryland is recalling bacteria-contaminated edibles. Virginia's medical cannabis sales are surging despite patient concerns. < Back D.C. Considers Extending Conditional Licenses to Four Years Amid ABCA Crackdowns, Maryland Recalls Bacteria-Contaminated Edibles, Sep 23, 2025 LJ Dawson Outlaw Report Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link D.C. Considers Extending Conditional Licenses to Four Years Amid ABCA Crackdowns, Maryland Recalls Bacteria-Contaminated Edibles, Virginia Medical cannabis Sales Surge Despite Patient Concerns Source < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Former NFL Star Talks Marijuana Rescheduling With Top Trump Administration Officials At White House Meeting < Back Former NFL Star Talks Marijuana Rescheduling... Jul 11, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A retired professional football player who’s since become an advocate for marijuana policy reform met with top Trump administration officials at the White House to discuss the ongoing federal cannabis rescheduling process. On Friday, former NFL player-turned-advocate Ricky Williams discussed the reform with high-level staffers across multiple agencies at the White House as part of a broader meeting that touched on cannabis. Officials with the U.S. Departments of Agriculture, Housing and Urban Development, Energy and White House Counsels Office were involved in the conversations, Marijuana Moment has learned. Williams, co-founder of Project Champion, told Marijuana Moment after the meeting that he’s “seen firsthand how cannabis can change lives—not just for wellness, but for opportunity.” “When I left the NFL, people questioned my choices. But for me, cannabis was part of my journey to healing—physically, emotionally, and spiritually,” he said. “I’m not alone in that experience. Veterans, cancer patients, and everyday Americans are all looking for safer, plant-based alternatives—and right now, federal law stands in the way.” “Rescheduling cannabis from Schedule I to Schedule III isn’t about politics—it’s about freedom. It’s about empowering small businesses, delivering tax relief, and creating jobs that count,” the athlete and influencer said. “It’s about aligning federal law with what’s already happening in 38 states. And most importantly, it’s about giving people safe, legal access to medicine that works.” “This reform is smart, it’s strategic, and it’s long overdue. Rescheduling helps us build a stronger economy, protect our communities, and ensure this industry benefits all Americans—including communities of color that have historically been left behind. I’m proud to stand here today to say: this is how we put America First.” Bruce Levell, who is a longtime advisor to Trump and has served as executive director of his National Diversity Coalition, was also at the meeting. He separately said in a social media post that he was “thrilled to share a highly productive meeting with [White House] senior staff, discussing President Trump’s transformative bill and its profound impact on urban and rural America.” “The Biden administration fell short on cannabis rescheduling, but we’re eager for our next conversation on moving to Schedule III,” he said, adding that Trump “is poised to deliver where others have not.” Thrilled to share a highly productive meeting with @WhiteHouse senior staff, discussing President Trump’s transformative bill and its profound impact on urban and rural America. The Biden administration fell short on cannabis rescheduling, but we’re eager for our next… pic.twitter.com/q4ByH4dPg6 — Bruce LeVell (@Bruce_LeVell) July 11, 2025 Meanwhile, on Monday, the Drug Enforcement Administration (DEA) again notified an agency judge that the marijuana rescheduling process remains stalled under the Trump administration. U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. was previously vocal about his support for legalizing cannabis, as well as psychedelics therapy. But during his Senate confirmation process in February, he said that he would defer to DEA on marijuana rescheduling in his new role. Separately, former Rep. Matt Gaetz (R-FL) was reportedly photographed reviewing a document that appears to be a draft contract to provide services—including “administration-related guidance”—to a firm affiliated with the major marijuana company Trulieve. The visible portion of the document describes a lucrative bonus if a certain “matter resolves,” with an “additional ‘Super Success Fee’” for other “exclusive policy remedies.” Last month, the former congressman reiterated his own support for rescheduling cannabis—suggesting in an interview with a Florida Republican lawmaker that the GOP could win more of the youth vote by embracing marijuana reform. Gaetz also said last month that Trump’s endorsement of a Schedule III reclassification was essentially an attempt to shore up support among young voters rather than a sincere reflection of his personal views about cannabis. A survey conducted by a GOP pollster affiliated with Trump that was released in April found that a majority of Republicans back a variety of cannabis reforms, including rescheduling. And, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter. Meanwhile, Trump picked former Florida Attorney General Pam Bondi (R) to run DOJ, and the Senate confirmed that choice. During her confirmation hearings, Bondi declined to say how she planned to navigate key marijuana policy issues. And as state attorney general, she opposed efforts to legalize medical cannabis. Amid the stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers recently reiterated that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges. Meanwhile, a newly formed coalition of professional athletes and entertainers, led by retired boxer Mike Tyson, sent a letter to Trump on Friday—thanking him for past clemency actions while emphasizing the opportunity he has to best former President Joe Biden by rescheduling marijuana, expanding pardons and freeing up banking services for licensed cannabis businesses. The post Former NFL Star Talks Marijuana Rescheduling With Top Trump Administration Officials At White House Meeting appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Advanced Flower Capital Inc. expanded its senior secured revolving credit facility to $50 million with an additional $20 million commitment. AFC will use the facility to fund commitments to existing borrowers, originate and participate in commercial loans to cannabis operators, and support working capital. The facility remains expandable to $100 million. Advanced Flower Capital Inc. (Nasdaq: AFCG) is a commercial mortgage real estate investment trust that provides institutional loans to state-law-compliant cannabis operators in the U.S. It is based in West Palm Beach, Florida. < Back Advanced Flower Capital Receives $20M Infusion Jun 10, 2025 Mg Magazine Newswire MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *WEST PALM BEACH, Fla. —* Advanced Flower Capital Inc. expanded its senior secured revolving credit facility to $50 million with an additional $20 million commitment from the facility’s lead arranger, an FDIC-insured bank with more than $75 billion in assets. AFC intends to use availability under the Credit Facility to fund commitments to existing borrowers, originate and participate in commercial loans to cannabis operators in line with its investment strategy, and support working capital and other general corporate purposes. The facility remains expandable to $100 million, subject to lender participation and available borrowing base. “This expanded commitment from a long-standing banking partner underscores the strength of our platform and strategy. This facility remains a core component of our financing approach, and we look forward to further strengthening this partnership as we scale our lending capabilities,” said Brandon Hetzel, AFC’s Chief Financial Officer. About Advanced Flower Capital Inc. Advanced Flower Capital Inc. (Nasdaq: AFCG) is a commercial mortgage real estate investment trust that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team’s network and credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value, and cash flows. It is based in West Palm Beach, Florida. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

A food technology company's patented dual-base gummy system is now available to producers in North America, Australia, and other global regions. < Back Melt-to-Make Expands Worldwide, Bringing Patented Gummy Technology and Clean Manufacturing Solutions to Global Markets Nov 6, 2025 Staff Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The food technology company’s patented dual-base gummy system is now available to producers across North America, Australia, and beyond. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Hemp producers can access carbon credit markets—both voluntary and compliance—by leveraging the crop's impressive carbon sequestration capabilities to create a new revenue stream and align with sustainability goals. Although opportunities exist, including potential tax credits through IRS Section 45Q, growers face challenges such as high verification costs, a lack of specific methodologies tailored for hemp, and regulatory ambiguity. < Back How Hemp Producers Can Unlock Potential In Carbon Credit Markets (Op-Ed) Dec 8, 2025 Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *“For hemp producers, entering the carbon credit market may provide a strategy for long-term sustainability and market resilience.”* *By Amy M. Rubenstein, Dentons* As the cannabis and hemp industries evolve (including most recently through an amendment to the 2018 Farm bill that redefines “hemp”), producers should seek innovative ways to diversify income and align their businesses with sustainability goals. One promising developments is integrating carbon credit generation into hemp cultivation practices. With its impressive carbon sequestration capabilities, hemp presents an untapped opportunity to access carbon credit markets, including tax incentives through IRS Section 45Q and credits in both voluntary and compliance markets. *Why Hemp Producers Should Care About Carbon Credits* Producers growing hemp for cannabinoids like Delta-8 THC, CBD and other intoxicating or therapeutic compounds face regulatory challenges and volatile market prices. The amended hemp definition in the federal spending bill compounds these issues and may push producers to find alternatives to monetize their hemp crops. If producers can show a qualifying end-use, they may be able to open up a new and increasingly valuable revenue stream while improving their environmental footprint. Hemp’s rapid growth rate and high biomass density make it particularly effective at capturing carbon dioxide, which is the foundation for generating carbon offsets. *Hemp’s Carbon Sequestration Power* To the Lincoln University Hemp Institute, “hemp is an ideal annual crop for carbon negative supply chains for food, feed, fiber and fuel.” According to the British Hemp Company, every metric ton of hemp cultivated can absorb approximately 1.63 metric tons of CO₂ from the atmosphere. Dr. Darshil Shah of the University of Cambridge has stated that industrial hemp can capture more carbon per hectare than forests or commercial crops like cotton or wheat. And unlike tree-planting offset schemes, hemp grows in four to six months, meaning it can be cycled multiple times per year for carbon drawdown. Its deep root system not only locks carbon into the soil but also improves soil structure and fertility over time, making future harvests more productive—and more carbon efficient. For hemp producers, especially those already investing in regenerative farming practices to improve cannabinoid yields and terpene profiles, these environmental benefits can be converted into quantifiable financial returns in the form of carbon credits. *Carbon Credit Markets: Voluntary vs. Compliance* There are two main avenues for selling carbon credits: 1. Voluntary Markets: These allow hemp growers to generate and sell carbon credits directly to companies, individuals or organizations looking to offset emissions as part of sustainability goals. Hemp-based credits are increasingly gaining attention here. Registries like Verra and Gold Standard are developing new agricultural methodologies to accommodate crops like hemp. 2. Compliance Markets: These are government-regulated systems like California’s Cap-and-Trade program or the European Union Emissions Trading System. While more complex to access, these markets offer higher and more stable credit prices. Hemp credits are not yet mainstream in compliance markets, but advocacy is growing for broader agricultural inclusion. One voluntary carbon credit example for hemp comes from Hempitecture, a U.S.-based company that builds sustainable construction materials from hemp, with a methodology being reviewed Verra. Each metric ton of carbon sequestered becomes a credit that a company can then purchase to reduce its overall carbon footprint. These credits have a marketplace, with a lower price commanded for the voluntary markets than the compliance markets. *IRS Section 45Q: A Primer for Hemp Cultivators* IRS Section 45Q provides tax credits for each metric ton of CO₂ captured and either permanently stored or used in an approved application. While IRS initially created this tax credit for large-scale industrial operations, recent interpretations and guidance suggest a growing openness to biological carbon sequestration—including agriculture-based solutions like hemp. However, for hemp to qualify under 45Q, a few key requirements must be met: 1. The CO₂ captured must be measured and verified using approved protocols. 2. The storage must be permanent or used in a qualifying end-use (e.g., biochar, building materials). 3. Entities must establish Monitoring, Reporting and Verification (MRV) systems to document sequestration. Because requirement #2 presents a challenge currently for intoxicating or therapeutic hemp-derived compounds (i.e., whether the carbon is captured permanently in that use case), most intoxicating hemp growers may find voluntary carbon markets (described above) to be a more immediate fit if 45Q’s requirements cannot be met. However, as intoxicating hemp producers may pivot when the new hemp definition becomes effective, using 45Q may become more attractive. It should be noted that IRS requirements under 45Q, which require compliance and monitoring standards (both during and after construction and placed in service), must be followed closely but still can allow flexibility on the use of the tax credit. Still, staying informed on IRS interpretations of 45Q is smart business—especially as policy continues to evolve as the 45Q credit has evolved and expanded under different administrations. *Creating Hemp-Based Carbon Credits: Navigating Compliance and Opportunity* Growers with sizable hemp acreage who want to turn hemp’s carbon sequestration into tradable credits must: 1. Measure carbon capture using accepted methodologies (such as COMET-Farm or Cool Farm Tool); 2. Work with a carbon project developer or aggregator. 3. Register with a verified carbon registry. 4. Undergo third-party validation and periodic verification. 5. Maintain long-term documentation and reporting. According to CarbonCredits.com, projects involving hemp are now being registered and monetized, with some platforms even exploring blockchain-based credit systems that tokenize offsets, allowing them to be traded more easily and transparently. While intoxicating hemp often has been separated from industrial-use hemp in regulations, it still qualifies for carbon credit opportunities as long as the cultivation methods meet the criteria for verifiable carbon sequestration. In the next year, this separation also may fade for hemp producers. From a marketing perspective for any hemp product, emphasizing environmental stewardship through carbon capture can also be appealing to eco-conscious investors and consumers. *Challenges to Consider* Before diving in, there are important caveats: - Verification costs can be substantial. Grouping together with other growers through a project developer can help. - Lack of clear hemp-specific methodologies. While some exist for soil carbon or biomass sequestration, few are tailor-made for intoxicating hemp crops. - Regulatory ambiguity. Federal policy still creates friction between cannabis-related operations and traditional agricultural benefits like USDA support or federal tax credits. Despite these issues, the carbon credit space continues to mature rapidly, and hemp growers are well-positioned to take early advantage. *The Future: Hemp as a Dual-Use Crop for Profit and Planet* For hemp producers, entering the carbon credit market may provide a strategy for long-term sustainability and market resilience. As more carbon registries develop agriculture-friendly protocols, and as public awareness of climate-smart agriculture grows, early adopters in the hemp space will reap financial and reputational benefits. Consumers seeking eco-friendly products may seek out products that have attributes like carbon capture. By aligning cultivation with carbon sequestration strategies and pursuing certification in voluntary or eventually compliance markets, hemp growers can play a pivotal role in fighting climate change—all while growing a better bottom line. *Amy M. Rubenstein is a partner in the Health Care practice at Dentons US LLP.* *Photo courtesy of Max Jackson.* The post How Hemp Producers Can Unlock Potential In Carbon Credit Markets (Op-Ed) appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The global cannabis industry is moving towards harmonized medical regulations and pharmaceutical-grade standards, while the U.S. remains fragmented, risking being sidelined in international trade. The Global Cannabis Regulatory Summit highlighted the need for unified global standards. Europe is leading in regulatory momentum with medical markets expanding and requiring pharma-grade protocols. U.S. rescheduling of cannabis to Schedule III could encourage investment but won't immediately open international trade for state-legal operators due to DEA restrictions. Experts advise U.S. operators to align with GMP standards and build international partnerships to prepare for future global integration. < Back Global Cannabis Playbook Emerges Amid U.S. Uncertainty Sep 24, 2025 Pam Chmiel MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link While international markets move steadily toward harmonized medical cannabis regulations, the United States remains mired in uncertainty. Without federal reform, U.S. operators risk being sidelined just as the groundwork for a global industry is being laid. Other countries are advancing with pharmaceutical-grade standards and unified frameworks, while the U.S. clings to a patchwork, recreational-first approach that may not meet international requirements. The question now is whether America can adapt quickly enough to join the conversation or be consigned to watching from the sidelines as others set the rules. Adding to the complexity, U.S. cannabis companies are up against global competitors with access to lower-cost labor, better cultivation climates, and more advanced infrastructure. All of this puts U.S.-based consumer packaged goods (CPG) brands hoping to compete globally at a disadvantage. Although the U.S. has the potential to lead in cannabinoid science and therapeutic development, the country risks being left behind in the global market. The disconnect between U.S. and international markets was a key topic at the inaugural Global Cannabis Regulatory Summit in Washington, D.C. — a landmark event that brought together regulatory, medical, and trade officials from seventeen countries. The summit marked the first coordinated international effort to align standards and set the groundwork for a unified global industry. Spearheaded and funded by Will Muecke and Stanton McLean, partners at London-based investment firm Artemis Growth Partners, the summit also focused on discouraging Europe from replicating the U.S.’s fragmented regulatory model. “It became very apparent that where we are in the cannabis cycle in Europe could easily turn into the U.S.’s fragmented system,” said Muecke, who — thanks to an Artemis office in San Jose, California — has watched the industry develop on both sides of the Atlantic. “We’re at a change point. We need a playbook of concrete steps to get to what we think is a very robust medical market.” He emphasized adult-use legalization in Europe depends on first ensuring a healthy medical industry. “If medical fails, then we’ll never get to adult use,” he said. “And I think right now we all see medical as a huge success.” To drive global cohesion, Artemis convened an invite-only group of regulators and policy leaders from the United Nations, European Union trade groups, U.S. state agencies, and international standards bodies including ASTM International, United States Pharmacopeia (USP), and the International Organization for Standardization (ISO). According to Muecke, the goal is to establish a permanent institution representing the entire global supply chain and serving as a trusted point of contact for regulators worldwide. “We hope to create a single, authoritative body regulators can engage with, whether that’s the INCB [International Narcotics Control Board], EU health ministries, or U.S. federal agencies once reform happens,” he said. “The current ‘walled garden’ approach in the U.S. won’t work on a global scale.” The shifting international landscape Despite a growing international reform movement, the global cannabis industry remains highly fragmented. Regions are progressing at markedly different speeds in terms of regulation and market development. In North America, for example, Canadian operators are expanding abroad because they’re facing flat domestic sales. At the same time, U.S. multistate operators (MSOs) remain boxed in by high taxes, limited capital access, and a continuing federal ban on interstate and international commerce. With medical markets expanding across twenty-one EU member states, Europe currently leads in regulatory momentum. Germany’s landmark legislation in April 2024 set the tone. Pilot programs in the Netherlands, Switzerland, and the UK are testing different models, with France and Greece preparing to scale up. However, progress in countries like Spain, Portugal, and Poland has slowed. In Latin America, exports are the primary focus. Colombia has emerged as a global leader in genetics and bulk supply. Brazil is steadily broadening medical access and easing penalties for personal use, but political and legal uncertainty continue to stymie Mexico’s potential. Oceania’s medical markets, particularly in Australia and New Zealand, are thriving, though regulatory scrutiny is increasing. Africa is still in the early stages of development; South Africa has legalized home cultivation, and Morocco is building out its infrastructure to support medical exports. Asia remains the most conservative region. Thailand recently backtracked on its adult-use legalization and is redesigning its regulatory framework, while Japan is cautiously expanding medical cannabis and CBD access under strict controls. International frameworks take shape In 2020, the World Health Organization (WHO) and United Nations took a landmark step by removing cannabis from Schedule IV of the Single Convention on Narcotic Drugs. The category is reserved for substances deemed to have little or no medical value. Althought the move didn’t legalize the plant globally or lift existing restrictions in member countries, rescheduling acknowledged the plant’s therapeutic potential and opened the door for expanded medical research and regulatory reform. At the heart of international enforcement is the INCB, one of four key bodies tasked with overseeing compliance with global drug-control treaties. Alongside the Commission on Narcotic Drugs, the WHO, and the UN Secretary-General, whose drug-related functions are carried out by the UN Office on Drugs and Crime, the INCB monitors adherence to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Despite growing public support and scientific validation of cannabis’s medical uses, enforcement remains complicated by a fragmented global legal landscape. Countries like Canada and Germany have adopted progressive regulatory frameworks, while others maintain a strict interpretation of international treaties. The patchwork presents challenges for the INCB as it navigates the tension between treaty compliance and national policy shifts driven by research, patient needs, political expediency, and consumer demand. Pharma-grade standards set the course The playbook by which a global industry will operate already is being written in Europe and other regions that are developing medical-first markets. The vast majority of these markets require pharmaceutical-grade protocols, including EU Good Manufacturing Practices (EU-GMP) and Good Agricultural and Collection Practices (GACP), as well as pharmaceutical-level laboratory testing. Cannabis medicines in Europe must meet the same stringent standards as other controlled substances under the UN’s Single Convention on Narcotic Drugs and national medicines acts. This means all producers of cannabis products must prove consistent chemical composition, define dosage forms, and verify efficacy. Lisbon-based Somai Pharmaceuticals is among the manufacturers with international aspirations who’ve surmounted the challenges. The company produces EU-GMP-compliant products in accordance with the EU’s herbal medicine pharmacopoeia and currently operates in twelve countries, with plans to expand to eighteen by the end of 2025. Under EU law, all herbal medicinal products must obtain marketing authorization before export, be evaluated by the European Medicines Agency, and be approved by the European Commission. Once authorized, products may be distributed in any EU nation that has legalized cannabis. “It takes roughly two and a half years to get through validation, batches, stability testing, and then regulatory approval for sales to multiple markets,” said Somai Chief Executive Officer Michael Sassano. “Without it, you can’t export to other countries.” Sita Schubert, Secretary General of the European Medicinal Cannabis Association and a leading voice on regulatory policy, sees this pharma-grade model as the foundation for the industry’s future in Europe. “The EU’s requirement for herbal medicines to have market authorization validates product quality, because it fulfills the EU-GMP standards. But the final part — clinical trials and proven efficacy for a specific indication — is still missing,” she said. Whether or not a company plans to develop a full pharmaceutical product, Schubert advises all operators to adopt rigorous standards from the outset. “For Americans thinking about entering the European market, you need to understand that we are a medical market. You need to think like pharma and act like pharma,” she said. Her message is clear: Companies must shed the U.S.’s “recreational mindset” and align with strict regulatory expectations to compete globally. Muecke also pointed to Germany as a model for what a functioning medical market should look like, including providing a legal pathway for developing and commercializing cannabinoid-based medicines. “If you were to create a cannabinoid medicine in Germany, you’d have a legal market to sell it into,” he said. “There’s no innovation in the U.S. on the medical side, because you have no way of selling a finished product.” Muecke believes moving the plant to Schedule III under the U.S. Controlled Substances Act could change that, giving pharmaceutical companies the green light to invest in cannabinoid drug development. As the law stands now, with cannabis planted on Schedule I alongside illegal drugs like heroin, opium, and fentanyl, there’s no incentive for American pharma companies to invest in developing new cannabinoid medications. Muecke estimates the opportunity represented by rescheduling could unlock a $100-billion global pharmaceutical segment driven by cannabinoid formulations. He and others argue that establishing and adhering to GMP-level standards isn’t about merely compliance; it’s also about building products that benefit both medical patients and recreational consumers. As the global market moves toward standardized quality and safety benchmarks, the U.S. risks being left behind. With no national requirement for GMP compliance, American brands may find themselves struggling to adapt when international trade barriers begin to lift. “How will the U.S. compete against markets delivering consistent, safe, pharmaceutical-grade products?” Muecke asked. “Because that’s what GMP means.” Standards bodies chart the path forward Mueuke identified ASTM International as “the tip of the spear” in pushing the industry toward pharmaceutical-grade standards. Together with ISO, ASTM is helping lay the groundwork for a globally interoperable system. Standardization begins at the plant level, spanning breeding, cultivation, manufacturing, dosage, and data collection. At the moment, ASTM is the only global organization with a working group devoted to developing performance and product safety standards for cannabis. Its Committee D37 on Cannabis has published more than sixty standards, with at least thirteen U.S. states adopting or referencing those standards in their regulatory frameworks. But significant gaps remain. “While the organization is a leading voice, there’s still a need for a central global body to coordinate just cannabis,” said David Vaillencourt, vice chairman of ASTM’s D37 committee. He noted a shortage of qualified technical experts across multiple domains as one hurdle to creating a set of unified standards. “We need pharmacists to help with dosing protocols for medical cannabis, hardware engineers for vaporizer standards, and toxicologists for evaluating formulations,” he said. Though thirty countries participate in ASTM standards-setting, representation from key scientific and regulatory voices remains limited. Vaillencourt also pointed to a critical disconnect between the cannabis industry and UN voting members and treaty experts familiar with the Single Convention on Narcotic Drugs. “That’s one of the last links to unify the global industry,” he said. “But many [experts and policymakers] have been reluctant to engage due to political sensitivity.” He applauded the Artemis team for bridging that divide by establishing a summit that attained buy-in from not only regulators, but also law enforcement. “Bringing two former members of the Bureau of International Narcotics and Law Enforcement to the Global Cannabis Regulatory Summit was a huge step forward,” Vaillencourt said. “It finally got the conversation going at a serious international level.” States begin looking beyond borders The Cannabis Regulators Association (CANNRA) is a nonpartisan, international association comprising government agencies that oversee cannabis and hemp regulation across more than forty-five U.S. states and territories, as well as four additional countries: Canada, the Netherlands, Malta, and Albania. While most members focus on implementing and enforcing policy in their own jurisdictions, conversations increasingly turn toward what international commerce may require. “This is still a nascent policy area, so state regulators are largely focused on making things work in their respective states,” said CANNRA Executive Director Gillian Schauer, PhD, MPH. “But we do have conversations about how regulations need to evolve for interstate commerce in the U.S. and how global trade may eventually impact regulations as well.” Schauer anticipates continued variation across state and national regulatory frameworks but stressed the importance of establishing shared minimum standards to ensure product safety and consumer protection. She pointed out the conversation is already underway in the hemp cannabinoid space, where interstate and even international commerce is quite lively. “The key is determining how individual governments can ensure products from other jurisdictions comply with their regulations,” she explained. “This could involve specific licensing and registration requirements, third-party certification programs that verify adherence to specific standards, or intergovernmental agreements that recognize certain jurisdictions as compliant. Or, it could mean a combination of all three.” Eventually, regulators will need to tackle deeper questions. How can regulatory systems effectively communicate across borders to support tracking and compliance? What parts of the supply chain are best suited for management at the local, state, or international level? “We’re not there yet in the U.S.,” Schauer admitted. “The state-by-state infrastructure was born out of necessity as states experimented with legalization in the absence of federal reform. That makes it difficult for states to think much beyond the task at hand in their own jurisdiction.” Will rescheduling change the game? According to attorney Jason Adelstone, who specializes in cannabis and international law at Harris Sliwoski LLP, rescheduling cannabis from Schedule I to Schedule III in the U.S. will do little, at least initially, to unlock international trade. “Not much will change as far as international trade goes because, still, only DEA registrants will be permitted to export and import marijuana,” he said, referring to the U.S. Drug Enforcement Administration. “State-legal operators will remain prohibited from accessing the international market.” Nevertheless, Adelstone believes there could be a major inflection point on the horizon if the DEA shifts its definition of medical cannabis away from the Food and Drug Administration-approved pharmaceutical model and moves toward a more EU-style botanical flower framework. Such a change could open the door for DEA-registered producers to supply medical-use products to Europe’s fast-growing markets, particularly Germany. “In all of my conversations with international businesses, people want DEA marijuana for their medical programs because of its perceived high quality standards,” said Adelstone. He believes the botanical medical model may serve as a “middle ground” between strict pharmaceutical systems and the broader adult-use market. “The middle ground is between pharmaceuticals, food, and supplements,” he explained. As a plant, “cannabis doesn’t fit into those three FDA approval lanes, so if the FDA created a pathway under the [Food, Drug, and Cosmetic Act] for botanical substances — like cannabis flower or psychedelic mushrooms — that could be a good middle ground for establishing the type of medical marijuana system you see in Europe.” Adelstone added another possible middle ground would be for the DEA to allow registered bulk manufacturers to export flower to countries that will utilize it in their medical systems. “Over time, production and sale by DEA registrants may normalize marijuana flower as a medical product in the U.S.,” he said, “which could lead to a domestic medical program and possibly even the botanical pathway I mentioned.” Adelstone already is seeing rapid momentum as international supply chains form despite the lack of U.S. participation. “The supply chains are being developed, and the language is being written,” he said. Even if U.S. companies can’t yet take part in cross-border commerce, now is the time to align operations, documentation, and terminology with international norms. Doing so, Adelstone said, will allow American companies to “integrate more seamlessly” once permitted. He also sees a rare first-mover opportunity for DEA-registered operations to insert themselves into the international supply chain, especially for scientific and, potentially, medical purposes. “If I were an MSO with money, I would be trying to acquire a DEA registrant right now,” Adelstone suggested, urging companies to begin laying the groundwork for compliant trade and strategic business relationships. In addition, he pointed to growing investor interest in international markets, emphasizing that even though U.S. companies are restricted from exporting, they can participate abroad. “It’s not explicitly in the statutes, but under current judicial precedent, operating a foreign marijuana company or investing in one does not violate the Controlled Substances Act,” he explained. Canadian companies like Organigram and High Tide are capitalizing on this window of opportunity by investing in EU cannabis supply chains through mergers, acquisitions, and international partnerships. What’s at stake now The Global Cannabis Regulatory Summit marked a strategic convergence of regulators, scientists, and industry leaders determined to build the next phase of a global economy. For the United States, the message was clear: Reform cannot be delayed forever without consequences. Yet the story is not finished. With its deep bench of scientific expertise, entrepreneurial drive, and consumer demand, the U.S. still holds the potential to help shape international norms — if it chooses to engage. By embracing medical-first frameworks and aligning with pharma-grade standards already in place abroad, American operators can position themselves to reenter the global conversation not as bystanders, but as partners.The opportunity remains, but it requires foresight. Rather than being locked out, the nation that sparked the legalization movement could still help lead its future — provided it seizes the moment. ------------------------------ Charting the Next Steps for a Global Cannabis Market 1. Why is global cannabis alignment important? A unified framework ensures product safety, trade consistency, and credibility with international regulators. Fragmented systems slow growth and increase compliance risks. 2. What role do pharmaceutical-grade standards play? EU-GMP and GACP standards are setting the baseline for international trade. Without pharma-level protocols, companies can’t access most global medical markets. 3. How does U.S. rescheduling affect global trade? Moving cannabis to Schedule III could encourage U.S. pharma investment, but DEA restrictions mean only registrants will initially access export channels. 4. What actions should U.S. cannabis operators take now? Experts recommend aligning operations with GMP standards, building international partnerships, and preparing compliance systems to integrate seamlessly once trade opens. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

PreRoll Press Inc. offers pre-roll manufacturing solutions to address challenges in the booming cannabis market, such as labor-intensive processes and inconsistent quality. Their systems optimize efficiency, reduce costs, and ensure high-quality pre-rolls, including the Fill N' Fold system with a Dutch Crown finish. They offer scalable systems for various production capacities and stand out with innovative solutions for infused pre-rolls, cost-effective equipment, and user-friendly design. Early adopters have reported significant improvements in labor and product consistency. PreRoll Press aims to empower producers and shape the future of cannabis production. < Back PreRoll Press Inc. Delivers Cutting-Edge Pre-Roll Manufacturing Solutions to Optimize Production May 2, 2025 Ganjapreneur Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link With the cannabis pre-roll market booming and sales exceeding $4.1 billion, this surge, driven by consumer demand for convenient, ready-to-use products, has exposed critical challenges for Processors, Producers and Stores: labor-intensive manual processes, inconsistent product quality, and scalability limitations. PreRoll Press Inc., a Spokane, Washington-based Pre roll machine manufacturer in cannabis equipment, has responded with a groundbreaking suite of pre-roll manufacturing solutions. PreRoll Press machines are designed to optimize efficiency, reduce labor costs, and deliver consistent, high-quality pre-rolls, enabling producers to thrive in a competitive market. *Redefining Pre-Roll Production: Precision, Speed, and Quality* Manual pre-roll production often leads to uneven pre-rolls and blunts, wasted materials, and production bottlenecks, making it difficult for producers to scale efficiently. PreRoll Press Inc. tackles these issues head-on with its flagship *Fill N’ Fold* system, a semi-automated solution that enables operators to fill, pack, and close up to 121 pre-rolls in less than ten minutes. By ensuring uniformity in density, shape, and appearance, this pre-roll machine ensures brand consistency and consumer satisfaction, critical in a market where quality drives loyalty. [image: Fill N Fold Patent Press Tool]*(Fill N Fold Patent Press Tool)* The *Fill N’ Fold* system is complemented by the patent-pending Press Tool, which applies a Dutch Crown-style finish to each pre-roll. Pressing Pre-rolls to close them prevents “canoeing” (uneven burning), minimizes paper waste, and increases visual appeal, making pre-rolls more attractive on retail shelves. Unlike traditional twisted-top finishes or manually Dutch Crowned pressed pre-rolls, this Dutch Crown system is designed to improve the smoking experience as pressed pre-rolls do not canoe and burn more evenly which increases perceived value, particularly for premium and infused pre-roll lines. These mechanical options are particularly adept at handling infused pre-rolls, which accounted for 44.4% of the pre-roll market and $1.75 billion in sales in the first half of 2024. Unlike systems that clog or jam when processing concentrates like distillate or live resin, PreRoll Press products ensure smooth, precise operation, making them a go-to choice for craft and premium producers and processors. *Scalable Systems for Every Producer* PreRoll Press Inc. recognizes that cannabis producers vary widely in scale and needs, from small boutique operations to large multi-state operators (MSOs). To address this diversity, the company offers modular, scalable systems tailored to different production capacities: *System* *Description* *Target Audience* *Single Tray System* Compact setup for filling and finishing 121 pre-rolls per run, ideal for small teams. Boutique growers, startups, R&D labs *Double and Triple Tray Systems* Supports multiple simultaneous runs, increasing output without added complexity. Mid-sized businesses, growing operations *All-In System* Comprehensive package with four tray sizes (109mm, 98mm, 84mm, 70mm), metering trays, packing bases, and press tools for versatile production. Producers needing a full range of sizes These pre-roll machines are designed for seamless integration, allowing producers and processors to scale operations as demand grows. For example, a startup using the Fill N Fold Single Tray System can later upgrade to the All-In System without overhauling their workflow, aligning with industry trends toward flexible automation Or They can even add 1 tray at a time if they are looking for steady scalability. *Competitive Advantages in a Crowded Market* In a market crowded with pre-roll equipment providers, PreRoll Press Inc. stands out by addressing real-world production challenges with innovative and unique solutions: 1. *Infused Pre-Rolls*: Engineered to handle sticky concentrates with ease of use, ensuring reliability for premium and infused product lines. 2. *Cost-Effective Innovation*: Offers commercial-grade equipment at competitive prices, starting at $1,850 for the Single Tray System, making advanced technology accessible without the expensive price tag. 3. *User-Friendly Design*: Intuitive systems require minimal training, supported by video tutorials, online documentation, and responsive customer support, enabling operators to master the equipment in hours. 4. *Built to Last*: Constructed with durable materials like ABS, Acetal, and HDPE, each system is backed by a limited lifetime warranty, ensuring long-term value and reliability. By leaning into versatility, durability, and affordability, PreRoll Press aims to be the preferred solution for producers and processors focused on delivering the highest quality products. *Real-World Impact: Producer Success Stories* Early adopters of PreRoll Press FIll N Fold Pre-roll Machines have reported phenomenal results. *Video Caption: Early adopter of Fill N Fold machine: it used to take 1 week for him to finish 500 Pre-rolls by hand, now he is able to complete 1 pound in 40 minutes.* *Skyler Keller from Growing Like A Weed LLC* shared, “Preroll Press is a game changer! We have fundamentally improved the labor required to make our prerolls with this innovative pre-roll machine. Not only do I highly recommend this system, but can’t say enough good things about the customer service too.” Another producer noted the system’s efficiency, producing 121 homogeneous pre-rolls in under 12 minutes, significantly reducing labor costs and improving product consistency. *A Legacy Rooted in Industry Expertise* Founded by cannabis industry veterans, PreRoll Press Inc. emerged from firsthand frustrations with inefficient production methods and overpriced equipment. The team’s deep understanding of the cannabis production floor drove the development of the patent-pending PreRoll Press, designed to deliver affordable, innovative pre-roll machines that exponentially increase production. Their mission is to empower producers with tools that simplify workflows, enhance quality, and drive profitability. PreRoll Press’s commitment to innovation extends beyond product development. The company recently partnered with Custom Cones USA and California Trim Store to expand its industry network, fostering collaboration and knowledge-sharing among cannabis professionals, and underscoring their dedication to supporting the broader cannabis ecosystem. *Looking Ahead: Shaping the Future of Cannabis Production* As the cannabis industry continues to mature, automation and precision will define the future of pre-roll production. PreRoll Press is leading this transformation, delivering solutions that enables producers to meet rising demand while maintaining quality and profitability. With a focus on innovation, accessibility, and customer success, the company is poised to shape the industry for years to come. Producers and processors interested in exploring PreRoll Press systems can visit www.prerollpress.co to request a custom quote or schedule a live demo. For direct inquiries, contact the sales team at sales@prerollpress.co or call +1-509-701-0035. *Media Contact* *PreRoll Press Inc.* Wes, Founder wes@prerollpress.co 509-701-0035 www.prerollpress.co < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5